Indegene (BOM:544172) Treasury Stock : ₹0 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Indegene Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Indegene's treasury stock for the quarter that ended in Dec. 2024 was ₹0 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Indegene Treasury Stock Historical Data

The historical data trend for Indegene's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indegene Treasury Stock Chart

Indegene Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Treasury Stock

Indegene Quarterly Data
	Mar21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Treasury Stock	Get a 7-Day Free Trial						-	-	-	-	-

Indegene Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Indegene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Indegene Ltd (BOM:544172) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

INDGN:India

Address

Outer Ring Road, Aspen Block G4, 3rd Floor, Manyata Embassy Business Park, Nagawara, Bengaluru, KA, IND, 560045

Website

https://www.indegene.com

Indegene Ltd provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations of life sciences companies. The company segment includes Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Key revenue is generated from the Omnichannel Activation segment.

Indegene Headlines

No Headlines